Weekly Investment Analysts’ Ratings Changes for WAVE Life Sciences (WVE)

A number of research firms have changed their ratings and price targets for WAVE Life Sciences (NASDAQ: WVE):

• 12/15/2025 – WAVE Life Sciences had its price target raised by analysts at Truist Financial Corporation from $36.00 to $50.00. They now have a “buy” rating on the stock.
• 12/13/2025 – WAVE Life Sciences was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/12/2025 – WAVE Life Sciences had its price target raised by analysts at B. Riley from $19.00 to $37.00. They now have a “buy” rating on the stock.
• 12/12/2025 – WAVE Life Sciences had its price target raised by analysts at Wedbush from $20.00 to $33.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – WAVE Life Sciences had its price target raised by analysts at Wells Fargo & Company from $16.00 to $29.00. They now have an “overweight” rating on the stock.
• 12/9/2025 – WAVE Life Sciences was given a new $30.00 price target on by analysts at UBS Group AG.
• 12/9/2025 – WAVE Life Sciences had its price target raised by analysts at Citigroup Inc. from $16.00 to $30.00. They now have a “buy” rating on the stock.
• 12/9/2025 – WAVE Life Sciences had its price target raised by analysts at Cantor Fitzgerald from $12.00 to $34.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – WAVE Life Sciences was upgraded by analysts at Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating. They now have a $27.00 price target on the stock, up previously from $9.00.
• 12/8/2025 – WAVE Life Sciences had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $21.00 price target on the stock.
• 12/8/2025 – WAVE Life Sciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $19.00 to $40.00. They now have a “buy” rating on the stock.
• 12/8/2025 – WAVE Life Sciences was given a new $28.00 price target on by analysts at Morgan Stanley.
• 12/8/2025 – WAVE Life Sciences had its “outperform” rating reaffirmed by analysts at Leerink Partners.
• 11/11/2025 – WAVE Life Sciences had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an “outperform” rating on the stock.
• 11/11/2025 – WAVE Life Sciences had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an “overweight” rating on the stock.
• 10/27/2025 – WAVE Life Sciences had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $12.00 price target on the stock.
• 10/20/2025 – WAVE Life Sciences is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $18.00 price target on the stock.

Insider Activity

In related news, Director Gregory L. Verdine sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.47, for a total transaction of $269,400.00. Following the sale, the director owned 275,217 shares in the company, valued at approximately $3,707,172.99. This trade represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Chris Francis sold 441,031 shares of WAVE Life Sciences stock in a transaction on Monday, December 8th. The shares were sold at an average price of $14.57, for a total value of $6,425,821.67. Following the completion of the sale, the insider directly owned 25,000 shares of the company’s stock, valued at approximately $364,250. This represents a 94.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 902,742 shares of company stock worth $13,313,763 in the last quarter. 23.98% of the stock is currently owned by corporate insiders.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.